Sinovac Biotech (北京科兴生物制品有限公司) continued its barrage of H1N1 flu vaccine news by announcing that its product passed an experts’ evaluation organized by the SFDA. After spending August 30 and 31 looking at data from the vaccine’s recent clinical trial, the experts recommended approval of the product. The data and the evaluation will be submitted to the SFDA, and Sinovac expects to be given a production license later this week. Sinovac's shares soared following the announcement. More details...

Stock Symbol: (NYSE Amex: SVA)